The lesion of the @entity35 substantia nigra pars compacta dopaminergic neurons as a model for XXXX .

@entity5212 @entity1 @entity859 @entity935 @entity73 @entity5834 @entity191 @entity4207 @entity35 @entity2414
1. In this article we review the studies of @entity2414 in a @entity35 model of @entity191 ( @entity191 ). 2. Intranigral administration of @entity5212 ( @entity5212 ) to @entity35 causes a partial lesion in the substantia nigra, compact part (SNc) and a specific loss of @entity935 and its metabolites in the striatum of @entity35 . 3. These animals present @entity4207 but no sensorimotor impairments, thus modeling the early phase of @entity191 when @entity73 are observed but the motor symptoms of the disease are barely present. 4. The @entity73 observed in these animals affect memory tasks proposed to model habit learning (the cued version of the water maze task and the two-way active avoidance task) and working memory (a working memory version of the water maze), but spare long-term spatial memory (the spatial reference version of the Morris water maze). 5. The treatment of these animals with levodopa in a dose that restores the striatal level of @entity935 does not reverse these @entity2414 , probably because this treatment promotes a high level of @entity935 in extrastriatal brain regions, such as the prefrontal cortex and the hippocampus. 6. On the other hand, the @entity859 receptor antagonist, @entity5834 , partly reverse the @entity2414 effect of SNc lesion in these @entity35 . This effect may be due to @entity5834 action on nigrostriatal neurons, since it induces @entity935 release and modulates the interaction between @entity859 and @entity935 receptor activity. 7. These results suggest that the MPTP SNc-lesioned @entity35 are a good model to study @entity2414 related to @entity191 and that @entity5834 and other selective A(2A) @entity859 receptor antagonists are promising drugs to treat this symptoms in @entity191 @entity1 .
